All In Biotech

Drug Trial Radar · NCT03829436

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Mar 20, 2019

Primary completion

Sep 7, 2022

Study completion Sep 7, 2022

Sponsor

Lead sponsor
Tempest TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.

Conditions

  • Hepatocellular Carcinoma
  • Metastatic Castration Resistant Prostate Cancer
  • Renal Cell Carcinoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Triple-Negative Breast Cancer
  • Urothelial Carcinoma
  • Cholangiocarcinoma
  • GastroEsophageal Cancer
  • Pancreatic Cancer
  • Sarcoma

Interventions

  • Part 1 TPST-1120Drug

    Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression

  • Part 2 TPST-1120 + nivolumabDrug

    Subjects will receive escalating doses of TPST-1120 administered orally twice daily

  • Part 3 TPST-1120Drug

    Selected dose of TPST-1120 administered orally twice daily until disease progression

  • Part 4 TPST-1120 + nivolumabDrug

    Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.Time frame: From start of treatment to end of treatment, up to 36 months
  2. Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab.Time frame: From start of treatment to end of treatment, up to 36 months
  3. Identify the maximum tolerated doseTime frame: From start of treatment to end of treatment, up to 36 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of California - San Francisco

    San Francisco, California

  • Miami Cancer Institute

    Miami, Florida

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Columbia University Medical Center

    New York, New York

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • University of Pennsylvania Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute - TN

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.